Cantor Fitzgerald Weighs in on Zura Bio FY2025 Earnings

Zura Bio Limited (NASDAQ:ZURA) – Analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of Zura Bio in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst J. Schimmer forecasts that the company will earn ($0.40) per share for the year. Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Zura Bio’s current full-year earnings is ($0.65) per share.

Zura Bio (NASDAQ:ZURA) last announced its earnings results on Thursday, November 7th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.12).

A number of other brokerages have also issued reports on ZURA. Leerink Partners started coverage on shares of Zura Bio in a research report on Monday, November 4th. They set an “outperform” rating and a $15.00 target price on the stock. Chardan Capital reduced their price objective on Zura Bio from $14.00 to $12.00 and set a “buy” rating on the stock in a report on Friday, November 8th. HC Wainwright reiterated a “neutral” rating and issued a $5.00 price objective on shares of Zura Bio in a research report on Tuesday, December 24th. Finally, Leerink Partnrs upgraded Zura Bio to a “strong-buy” rating in a research report on Monday, November 4th. One investment analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $15.80.

Zura Bio Trading Down 3.9 %

Shares of NASDAQ ZURA opened at $1.72 on Thursday. Zura Bio has a 12-month low of $1.67 and a 12-month high of $6.35. The firm’s 50-day simple moving average is $2.48 and its 200 day simple moving average is $3.46.

Hedge Funds Weigh In On Zura Bio

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp raised its position in shares of Zura Bio by 15.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 47,109 shares of the company’s stock valued at $165,000 after acquiring an additional 6,412 shares during the period. Renaissance Technologies LLC raised its holdings in Zura Bio by 51.3% in the second quarter. Renaissance Technologies LLC now owns 17,400 shares of the company’s stock worth $61,000 after purchasing an additional 5,900 shares during the period. Armistice Capital LLC raised its holdings in Zura Bio by 53.2% in the second quarter. Armistice Capital LLC now owns 2,524,000 shares of the company’s stock worth $8,834,000 after purchasing an additional 876,000 shares during the period. AQR Capital Management LLC bought a new position in shares of Zura Bio during the second quarter worth $43,000. Finally, Forefront Analytics LLC grew its holdings in shares of Zura Bio by 22.1% in the 2nd quarter. Forefront Analytics LLC now owns 41,569 shares of the company’s stock valued at $145,000 after buying an additional 7,531 shares during the period. Institutional investors own 61.14% of the company’s stock.

Insiders Place Their Bets

In related news, Director Parvinder Thiara sold 1,001,633 shares of Zura Bio stock in a transaction on Monday, November 25th. The stock was sold at an average price of $2.73, for a total transaction of $2,734,458.09. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 22.10% of the company’s stock.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.